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Introduction 
 
Microchimerism, the co-existence of a small 
number of cells which originate from a geneti-
cally distinctive individual often results from 
bone marrow transplantation where donor cells 
can be detected in recipient tissues (reviewed in 
[1]). It has recently become clear however that 
more common forms of microchimerism exist, 
namely, maternal and foetal microchimerism 
resulting from the bi-directional transfer of cells 
in pregnancy. The engraftment of maternal cells 
in the foetus is known as maternal microchimer-
ism (MMc) while cell transfer in the opposite 
direction called foetal microchimerism (FMc) 
(Figure 1).  
 
The phenomenon of maternal microchimerism 
was initially recognized in children with severe 
combined immunodeficiency more than 20 
years ago [2] and maternal cells were identified 
in umbilical cord blood samples from male in-
fants in 1995 [3]. The placenta is therefore not 
an impenetrable barrier to cellular traffic. It has 
been shown that microchimeric cells persist for 
many years in healthy individuals; foetal cells 
have been found in maternal blood up to 27 
years postpartum [4] and maternal cells have 
been detected in her offspring for up to 49 
years [5].  
 
The maternal immune system was initially 
shown to be exposed to foetal microchimeric 
cells at 15-27 weeks gestation [6] and subse-
quently even as early as 5-6 weeks gestation 
[7]. Foetal DNA has been detected in both the 
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cellular and cell-free compartments of maternal 
blood beginning at 7-16 weeks but rising after 
24 weeks and reaching a peak at birth [8]. After 
birth it has been found that the levels of foetal 
microchimeric cells are significantly higher than 
that of maternal microchimeric cells [9, 10].  
 
In genetics, detection of fetal DNA in maternal 
blood has had greatest relevance in prenatal 
diagnosis where early non-invasive prenatal 
testing for cell free fetal DNA in maternal blood 
has translated into clinical practice for some 
genetic traits (reviewed in Wright and Chitty BMJ 
2009) [11]. Microchimeric cells have however 
potentially much broader relevance including 
the induction and maintenance of immune tol-
erance to genetically distinct (allogeneic) cells; 
contributing to susceptibility and resistance to 
disease, especially autoimmune disease and 
possibly also to tissue repair.  
 
Most studies of microchimerism have focused 
on analysis of haematopoietic cells but it is in-
creasingly clear from human [12, 13] and ani-
mal [14] studies that microchimeric cells also 
exist in other tissues including the liver, heart 
and brain supporting the thesis that some cells 
that cross the placental barrier in each direction 
are stem cells with multilineage potential 
[15,16].  
 
Study of microchimerism has been restricted 
over the past two decades by technological limi-
tations in studying rare event cells. Studies of 
microchimerism in humans have been limited 
to: 1) Genetic epidemiological studies of the 
frequency of non-inherited maternal alleles 
(NIMA) in affected compared to control individu-
als. These studies require large well character-
ized patient populations to generate robust as-
sociations. 2) Quantitative PCR analysis of the 
level of the NIMA in disease versus health. 3) 
Detection of the Y chromosome by PCR in ma-
ternal DNA and 4) Direct detection and quantifi-
cation of female cells in autopsy tissue sections 
from male offspring (and male cells in maternal 
tissue) by fluorescence in situ hybridization 
(FISH) with concomitant cellular phenotyping by 
immunohistochemistry. 
 
More recently animal models of microchimerism 
have been developed which tag maternal or 
foetal cells with for instance green fluorescent 
protein (GFP) allowing MMc to be followed [17]  
 
Pregnancy is, by definition, a period of immune 
privilege and it is well established that the bal-
ance of immune mediators promotes mainte-
nance of the foetal “graft”. The persistence of 
maternal cells implies that her offspring is toler-
ant to a low level of genetically distinct antigen. 
The mechanism underlying this naturally ob-
tained tolerance is unknown but is supported by 
the observation of improved survival of renal 
transplants from sibling donors who share the 
non-inherited maternal HLA with the recipient 
[18]. Increased levels of microchimerism, both 
foetal and maternal, have however also been 
associated with autoimmunity. 
 
Microchimerism in autoimmunity 
 
Although microchimeric cells exist in very low 
numbers in healthy individuals, it has been sug-
gested that they are involved in the pathogene-
sis of autoimmune diseases. Interestingly auto-
immune diseases are more common in women 
than men and most commonly develop in 
women of childbearing age or older.  
 
Chronic graft-versus-host disease (cGvHD), a 
common complication of bone marrow trans-
plantation has clinical similarities to some auto-
immune diseases (including the development of 
autoantibodies) i.e. Sjögren syndrome and Sys-
temic Sclerosis [19]. Susceptibility to cGvHD is 
associated with incompatibility between the HLA 
genes expressed by the “invading” population 
Figure 1. Schematic diagram of a pregnant woman 
with transfer of foetal cells (white)  to the mother and 
maternal cells  (black) to the foetus.  Maternal stem 
cells are red while foetal stem cells are green.  
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from the donor and those of the recipient. Given 
that most autoimmune diseases like rheuma-
toid arthritis and type 1 diabetes occur in sub-
groups of the population carrying certain HLA 
genes it is reasonable to argue that HLA 
“incompatible” alleles from the invading micro-
chimeric population may cause a similar reac-
tion in these genetically susceptible individuals. 
This might suggest that microchimerism result-
ing from transplantation and microchimerism 
resulting from pregnancy have similar mecha-
nisms by which they influence the immune sys-
tem. 
 
In this review, studies suggesting that the role 
of microchimeric cells in disease can be either 
beneficial or detrimental will be discussed:  
 
Foetal microchimerism in autoimmune diseases 
 
Systemic sclerosis (SSc) 
 
Systemic sclerosis (also called scleroderma) is 
clinically heterogeneous, chronic immunological 
disorder characterized by increased collagen 
deposition in the skin and various internal or-
gans and is associated with a cellular infiltrate 
consisting primarily of T lymphocytes. A role for 
fetal microchimerism in SSc was first reported 
by Nelson et al. in 1998 [20] when women with 
systemic sclerosis had significantly higher levels 
of male DNA, as detected by Y chromosome 
specific PCR, than controls. Several subsequent 
studies from this group and others have repli-
cated this observation and revealed that FMc in 
SSc patients are CD3+, CD4+ and CD8+ T lym-
phocytes with populations enriched in CD4+ 
subset, and they express CD25+ T cell activation 
marker [21, 22].   
 
Autoimmune thyroiditis  
 
Hyperthyroidism (Graves’ disease) and hypothy-
roidism (Hashimoto’s thyroiditis) are generally 
considered to be most prevalent in middle aged 
females particularly those who have had chil-
dren and nearly two thirds of newly diagnosed 
Graves’ disease cases in women with children 
occur within one year of delivery [23].  
 
Several studies have shown that FMc was more 
frequent in thyroid tissue from patients with 
Hashimoto’s thyroiditis and Grave’s disease 
compared to control tissue [24, 25, 26, 27]. In 
cases where attempts have been made to phe-
notype the FMc, they have been described as 
expressing epithelial [25] and lymphocyte mark-
ers [27].  
 
These data are complemented by observations 
in a mouse model of autoimmune thyroiditis 
where FMc was identified in 12 of 26 mice with 
autoimmunity compared to 2 of 10 controls. In 
this study the fetal cells had an immune cell 
phenotype (T cells and dendritic cells) [28]. 
 
Systemic lupus erythematosus (SLE) 
 
Healthy women with no history of autoimmune 
disease and women diagnosed with systemic 
lupus erythematosus (SLE) were studied to as-
certain levels of foetal microchimeric cells. Both 
groups of women had previously given birth to 
at least one son. DNA was extracted from 
PBMCs and quantitative real time PCR of the 
SRY locus on the Y chromosome was used to 
measure levels of male foetal DNA. Levels of 
FMc in women with SLE were significantly 
higher than healthy control women (P = 0.034; 
OR = 4.22) [29]. Interestingly in this study it was 
also found that, although not statistically signifi-
cant, levels of foetal microchimeric cells were 
higher in mothers with older sons suggesting 
time since the delivery is directly proportional to 
levels of foetal microchimerism.  The authors 
speculate that this observation suggests that a 
foetal cell lines become established over time. 
The number of subjects analysed in this study 
was however relatively small (18 healthy control 
women compared to 28 women sufferig from 
SLE).  
 
Rheumatoid arthritis 
 
It has been reported that approximately 75-90% 
of mothers that suffer from rheumatoid arthritis 
(RA) found that their symptoms improve sponta-
neously during the second or third trimester of 
pregnancy, but return within 3-4 months after 
delivery [30, 31, 32]. The explanation for this 
effect remains unknown, but it has been pro-
posed that HLA-DR and DQ antigen incompati-
bility between mother and child suppresses the 
maternal immune system during pregnancy and 
RA improves [33]. Indeed a study of serum foe-
tal DNA levels showed an association with dis-
ease activity in pregnant women with RA [34].  
 
Foetal Microchimerism and cancer 
 
A recent focus of studies of microchimerism is 
cancer. FMc were identified in 50% of papillary 
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thyroid tumors by Srivarsa et al. [12] while FMc 
positive for the lymphocytic marker, CD45, were 
detected in papillary thyroid cancer in 2008 by 
Cirello and colleagues [35]. When DNA was ex-
tracted from peripheral blood from 99 parous 
women, 54 with primary invasive breast cancer 
and 45 general population controls. Women 
harboring FMc were less likely to have had 
breast cancer (p = 0.02) and FMc concentra-
tions were higher in controls versus cases (p = 
0.01) [36].  In a larger case-control follow up 
[37] the same researchers replicated their ob-
servation and hypothesized that parous women 
with breast cancer fail to harbor a potential 
source of naturally acquired allogeneic immu-
nity. Further research is required to characterize 
this potentially protective subset of FMc.  
 
Maternal microchimerism in autoimmune     
diseases 
 
Systemic sclerosis  
 
Foetal microchimerism has been associated 
with SSc, as described above, but there are also 
data supporting a role for MMc in this condition. 
Long-term persistent MMc have been discov-
ered in the peripheral blood of SSc patients as 
well as healthy controls up to 49 years of age 
[5]. Quantitative PCR revealed that MMc oc-
curred more frequently among women with SSc 
(72%) compared to healthy controls (22%) 
(Odds ratio 9.3, P=0.001), but the levels of 
MMc (expressed as genome equivalent of ma-
ternal cells per million, gEq/mil) were not signifi-
cantly different (0-68.6 gEq/mil in SSc patients, 
0-54.5 in healthy women) [38]. Additional analy-
sis of MMc levels in bone marrow and in multi-
ple tissues from a patient who died of SSc strik-
ingly showed that even if absent in the periph-
eral blood, significantly high levels of MMc could 
still be detected in lung, heart, spleen, and in 
pancreas while 10-20-fold lower levels were 
observed in bone marrow and gut [38]. Both 
FMc and MMc can therefore be detected in SSc 
patients and are thought to contribute to SSc 
aetiology. However, whether MMc function simi-
larly or differently to FMcs, what immune chal-
lenges they present to the host are still unclear.  
 
Neonatal lupus syndrome 
 
Neonatal lupus syndrome (NLS) occurs in utero. 
Infants born to mothers with anti-Ro and anti-La 
antibodies have a high risk of developing NLS, 
resulting in severe inflammation including con-
genital heart block. Employing a fluorescent in 
situ hybridisation (FISH) assay, MMc were de-
tected in 15 of 15 sections of NLS heart tissue, 
and their frequencies ranged from 0.025% to 
2.2% of total cells. By contrast, maternal cells 
were found in only 2 of 8 control sections (0-
0.1% of total cells). Subsequent immunohisto-
chemistry assay showed that only very few of 
these MMc expressed hematopoietic marker 
CD45, yet 86% of them expressed sarcomeric 
alpha-actin (a specific marker for cardiac myo-
cytes) [13]. These data indicate that MMc in 
neonatal somatic tissue represent differentiated 
tissue-specific cells which may be targeted by 
host immune system.   
 
Juvenile dermatomyositis 
 
Juvenile dermatomyositis (JDM) is a multisys-
tem autoimmune disease that results from in-
flammation of the small vessels of the muscle, 
skin, gastro-intestinal tract and other organs. 
Involvement of the immune system in JDM has 
been demonstrated by the presence of lympho-
cytic and phagocytic infiltrates in muscle biop-
sies from children with JDM [39] and associa-
tion with the human leucocyte antigen (HLA) 
class II allele DQA1 *0501 [40]. Recent studies 
investigated maternal microchimerism in JDM 
[41, 42, 43]. Maternally derived chimeric cells 
were shown to be present more often in muscle 
biopsies from children with JDM compared to 
controls. Analysis of whole blood DNA by qPCR 
demonstrated increased MMc in children with 
JDM compared to their healthy siblings. Further, 
in unrelated healthy offspring the presence of 
chimerism was shown to be associated with 
HLA genotype of the mother, in particular HLA 
DQA1*0501 [43]. Experiments on peripheral 
blood lymphocytes showed that maternally de-
rived microchimeric cells are activated when 
exposed to the JDM child’s lymphocytes indicat-
ing that MMcs are immunologically active and 
may play a direct role in the disease process.  
 
Type 1 Diabetes 
 
Type 1 Diabetes (T1D) is characterized by insu-
lin deficiency resulting from autoimmune de-
struction of insulin secreting islet beta cells with 
lymphocytic and macrophage infiltration of the 
pancreas.  
 
Using qPCR to detect the non-inherited mater-
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nal HLA allele in peripheral blood DNA, MMc 
were shown to be present in higher levels in 94 
individuals with T1D compared to 54 unaffected 
siblings and 24 unrelated healthy subjects [44]. 
Employing a FISH assay to detect MMc in pan-
creatic tissue from a patient with T1D compared 
to healthy controls with concomitant immuno-
histochemistry to stain for insulin and CD45 (a 
marker for haematopoietic cells), insulin stain-
ing, presumed beta cells were observed at 
higher levels in the T1D pancreas. Only very few 
of the maternal cells in the pancreas stained for 
CD45, indicating that it is unlikely that MMc act 
as effectors in the autoimmune response in T1D 
although further studies are necessary to inde-
pendently replicate this observation. Nelson et 
al suggested that increased levels of insulin 
staining MMc in T1D pancreas may suggest that 
these cells play a role in the repair of damaged 
tissue. Further studies have confirmed the pres-
ence of maternal cells in T1D pancreas (Figure 
2) that stain positively for insulin but more de-
tailed phenotyping is required to define the role 
of MMc in the pancreas. 
 
Microchimerism and genetic disease 
 
The frequency of microchimerism appears to be 
increased when foetal cytogenetic abnormali-
ties occur. In a study by Bianchi et al [45] the 
mean number of male foetal cells present in the 
mother when the foetus has Down’s syndrome 
was elevated 6–fold compared to women with 
normal male foetuses and in the study by Sri-
vatsa et al. [12] of maternal microchimerism in 
newborn tissues, MMc levels were highest in 
the thymus of a child with Down’s syndrome 
and non-immune hydrops.  One potential expla-
nation therefore of the intriguing epidemiologi-
cal observation that risk of Alzheimer’s disease 
(AD) is increased in the mothers of children with 
Down’s Syndrome [47] could be engraftment of 
foetal DS cells in the maternal brain. There is 
however, as yet, no proof for this hypothesis. 
 
The Future of Microchimerism 
 
As represented in Figure 3 microchimeric cells, 
both foetal and maternal have been identified in 
a variety of tissues with differing phenotypes. 
Depending on the disease scenario data have 
been generated to support a variety of hypothe-
ses: it is possible that MMc are 1. effectors of 
the immune response 2. targets of the immune 
response or indeed  3. beneficial with regard to 
tissue repair and cancer recognition. More evi-
dence is needed to clarify the role of microchi-
meric cells in autoimmunity and cancer. This 
 
Figure 2. Some organs where microchimeric cells have been associated with autoimmunity. 
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area of research is largely operating at the limi-
tations of technical capability: Microchimerism 
is currently detected largely using two strate-
gies: 1. using qPCR either for the non-shared, 
non-inherited maternal allele when maternal 
genotyping is available or for the presence of Y 
markers in female tissue or 2. Detection of fe-
male cells in male tissue or male cells in female 
tissue. As biological techniques become more 
sophisticated it should be possible to phenotype 
MMc in tissue sections more easily allowing 
definitive analysis of microchimeric calls and 
strategies to either target or enhance microchi-
meric cells for therapeutic benefit as appropri-
ate.  
 
Although steady developments in the field of 
microchimerism have occurred over the last two 
decades, this is effectively a new field which has 
been hampered by the complexity of the tech-
niques required to analyse these rare cells in 
detail.  Emerging technologies such as the abil-
ity to isolate and analyse individual microchi-
meric cells by laser capture microscopy will pro-
vide new insights into whether microchimerism 
is simply natural physiology or natural physiol-
ogy with the capacity to contribute to our under-
standing of disease mechanisms as well as cel-
lular differentiation and repair.  
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